Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Adverse Events During ART and Implications for Treatment: Key Data From Summer 2021
  • CME
  • CE

Eric S. Daar, MD
Released: September 22, 2021
Back Next

References

  1. Orkin C, Molina J-M, Supparatpinyo K, et al. The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: results from the DRIVE-AHEAD clinical trial. Presented at: 2021 International AIDS Society Conference on HIV Science; July 18-21, 2021. Abstract 709.
  2. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68:535-544.
  3. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) Versus efavirenz/emtricitabine/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial. Clin Infect Dis. 2021;73:33-42.
  4. Wang R, Wright J, George N, et al. Comparison of viral replication for the 2-drug regimen (2DR) of dolutegravir/lamivudine (DTG/3TC) versus a 3/4-drug tenofovir alafenamide-based regimen (TBR) in the TANGO study through week 96. Presented at: Presented at: 2021 International AIDS Society Conference on HIV Science; July 18-21, 2021. Abstract OAB0301.
  5. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71:1920-1929.
  6. Llibre JM, Alves C, Cheng CY, et al. Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA). Presented at: 2021 International AIDS Society Conference on HIV Science; July 18-21, 2021. Abstract OALB0303.
  7. Maggiolo F, Rizzardini G, Moline J-M, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial. Presented at: 2021 International AIDS Society Conference on HIV Science; July 18-21, 2021. Abstract 784.
  8. Milic J, Renzetti S, Ferrari D, et al. Switch to INSTI more than offset negative effects of weight gain on incidence of insulin resistance in people living with HIV. Presented at: 2021 International AIDS Society Conference on HIV Science; July 18-21, 2021. Abstract 2259.
  9. McComsey G, Molina J-M, Yazdanpanah Y, et al. Week 96 metabolic and bone outcomes of a Phase 2b trial of islatravir and doravirine. Presented at: 2021 International AIDS Society Conference on HIV Science; July 18-21, 2021. Abstract 1017.
  10. Molina JM, Yazdanpanah Y, Afani Saud A, et al. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Lancet HIV. 2021;8:e324-e333.
  11. Kumar P, Johnson M, Molina JM, et al. Brief report: switching to DOR/3TC/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial. J Acquir Immunde Defic Syndr. 2021;87:801-805.
  12. Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124-1135.
  13. Orkin C, D’Amico R, Bernal Morell E, et al. Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population). Presented at: 2021 International AIDS Society Conference on HIV Science; July 18-21, 2021. Abstract OAB0302.

 

Back Next

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue